A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.

Abstract

Amonafide demonstrated a poor response rate and substantial toxicity in patients who had measurable, advanced mixed mesodermal tumors of the uterus. Amonafide-a drug that acts through intercalation of tumor DNA-was used to treat 16 patients who had measurable, advanced mixed mesodermal tumors of the uterus as part of a Gynecologic Oncology Group (GOG) Phase II study. The starting dose was 300 mg/m2 intravenously over 1 hour for 5 consecutive days every 3 weeks. Severe or life-threatening hematologic toxicity occurred in 50% of the patients. Two patients experienced vomiting requiring hospitalization. Other toxicities were not severe. One patient had a partial response and one had stable disease, each lasting 4 months. This dose schedule was associated with poor response rate and substantial toxicity.

• Authors: R Asbury, J A Blessing, E Podczaski, H Ball
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 21 Issue 3 Pg. 306-7 (Jun 1998) ISSN: 0277-3732 [Print] United States
• PMID: 9626805 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Imides
• Isoquinolines
• Naphthalimides
• Organophosphonates
• amonafide
• Adenine

Topics

• Adenine
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (adverse effects, therapeutic use)
• Female
• Humans
• Imides (adverse effects, therapeutic use)
• Isoquinolines (adverse effects, therapeutic use)
• Leukopenia (chemically induced)
• Middle Aged
• Mixed Tumor, Mesodermal (drug therapy)
• Naphthalimides
• Organophosphonates
• Thrombocytopenia (chemically induced)
• Uterine Neoplasms (drug therapy)